EKF Ekf Diagnostics Holdings Plc

TIDMEKF

RNS Number : 9916A

EKF Diagnostics Holdings PLC

17 September 2018

EKF Diagnostics Holdings plc

("EKF" or the "Company")

Notice of results

EKF Diagnostics Holdings plc (AIM: EKF), the AIM listed point-of-care business, announces that it will release its interim results for the six months ended 30 June 2018 on Wednesday 19 September 2018.

Enquiries:

 
EKF Diagnostics Holdings plc 
Christopher Mills, Non-Executive Chairman                                  Tel: 029 2071 0570 
Julian Baines, CEO 
 
Richard Evans, FD & COO 
N+1 Singer (Nominated Adviser & Broker)                                    Tel: 020 7496 3000 
Aubrey Powell / Lauren Kettle / George Tzimas (Corporate Finance) 
 Tom Salvesen (Corporate Broking) 
 
 
Walbrook PR Limited                                  Tel: 020 7933 8780 or ekf@walbrookpr.com 
Paul McManus / Lianne Cawthorne                            Mob: 07980 541 893 / 07584 391 303 
 
 
 
 
 

About EKF Diagnostics Holdings plc www.ekfdiagnostics.com

EKF is a leading point-of-care diagnostics and central laboratory assay manufacturer with an estimated 80,000 hemoglobin, hematocrit, HbA1c, glucose and lactate analyzers in regular use across more than 100 countries. EKF specializes in developing tests for use in anemia and diabetes diagnosis and management, as well as providing a portfolio of reagents for use in clinical chemistry analyzers.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

NORMMGMLMNNGRZM

(END) Dow Jones Newswires

September 17, 2018 07:21 ET (11:21 GMT)

Ekf Diagnostics (LSE:EKF)
Historical Stock Chart
From Apr 2024 to May 2024

Ekf Diagnostics (LSE:EKF)
Historical Stock Chart
From May 2023 to May 2024